Cogent Biosciences Files NDA for Bezuclastinib in GIST
WALTHAM, Mass. and BOULDER, Colo., April 1, 2026 Cogent Biosciences, Inc. has announced the successful submission of a New...
FDA NDA
Advertisement
Merck’s Two-Drug HIV Therapy Shows Strong Phase 3 Efficacy
RAHWAY, N.J. – October 15, 2025 — Merck (NYSE: MRK) announced new Phase 3 trial results for its investigational,...
Advertisement
